Jazz Pharmaceuticals plc
NASDAQJazz Pharmaceuticals reports Q2 earnings on August 5 against a backdrop of unusually broad analyst conviction — and options markets that have quietly grown more cautious in recent weeks. The clearest pre-earnings signal sits in options positioning, which has shifted noticeably toward defense. The put/call ratio has climbed to 1.00, above its 20-day average of 0.92 — a move that…
JAZZ cost to borrow surges 126% in one week to 0.38%, signaling rising short-covering pressure as short interest declines 5.9% over the same period.
Jazz Pharmaceuticals reports Q2 earnings on August 5 against a backdrop of unusually broad analyst conviction — and options markets that have quietly grown more cautious in recent weeks. The clearest pre-earnings…
Jazz Pharmaceuticals heads into August earnings with short sellers rebuilding positions and the entire C-suite selling stock — a twin pressure point that makes the current $243.82 price more contested than the flat…
Snapshot as of 6 Aug 2026
Jazz Pharmaceuticals heads into the back half of June with short sellers continuing their retreat and the Street firmly bullish — yet the stock has drifted lower since the last note, raising a quiet question about…
Jazz Pharmaceuticals enters mid-June with an unusual combination: short sellers are beating a sustained retreat while analysts are racing to lift their targets — and Bank of America fired the latest shot this…
Jazz Pharmaceuticals heads into late May with shorts in full retreat — a month-long covering wave that has cut short interest nearly in half, even as a fresh wave of analyst upgrades pushes price targets well above the…
Jazz Pharmaceuticals just delivered its strongest quarterly beat in years — and the positioning data shows shorts were already getting out of the way before the numbers hit. Q1 2026 revenue came in at $1.07 billion, up…
Jazz Pharmaceuticals heads into its May 6 Q1 earnings report with short sellers meaningfully on the back foot after a sharp squeeze in late April. The short interest story has been the defining positioning move of the…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for JAZZ — free to start on ORTEX.
Sign up for free →Open JAZZ on ORTEX